GSA Capital Partners’s Heron Therapeutics HRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $615K | Buy |
+297,321
| New | +$615K | 0.04% | 773 |
|
|
2024
Q4 | – | Sell |
-512,736
| Closed | -$1.02M | – | 1777 |
|
|
2024
Q3 | $1.02M | Buy |
512,736
+79,680
| +18% | +$159K | 0.08% | 455 |
|
|
2024
Q2 | $1.52M | Buy |
433,056
+153,357
| +55% | +$537K | 0.11% | 272 |
|
|
2024
Q1 | $775K | Sell |
279,699
-59,749
| -18% | -$166K | 0.06% | 615 |
|
|
2023
Q4 | $577K | Buy |
+339,448
| New | +$577K | 0.05% | 700 |
|
|
2023
Q2 | – | Sell |
-64,528
| Closed | -$97K | – | 1688 |
|
|
2023
Q1 | $97K | Sell |
64,528
-52,046
| -45% | -$78.2K | 0.01% | 1366 |
|
|
2022
Q4 | $291K | Buy |
116,574
+30,115
| +35% | +$75.2K | 0.04% | 946 |
|
|
2022
Q3 | $365K | Sell |
86,459
-114,965
| -57% | -$485K | 0.05% | 804 |
|
|
2022
Q2 | $562K | Buy |
201,424
+53,152
| +36% | +$148K | 0.08% | 427 |
|
|
2022
Q1 | $848K | Buy |
148,272
+113,898
| +331% | +$651K | 0.11% | 243 |
|
|
2021
Q4 | $314K | Sell |
34,374
-2,068
| -6% | -$18.9K | 0.04% | 897 |
|
|
2021
Q3 | $390K | Sell |
36,442
-23,651
| -39% | -$253K | 0.04% | 851 |
|
|
2021
Q2 | $933K | Buy |
60,093
+26,724
| +80% | +$415K | 0.11% | 285 |
|
|
2021
Q1 | $541K | Buy |
+33,369
| New | +$541K | 0.09% | 309 |
|
|
2020
Q4 | – | Sell |
-42,177
| Closed | -$625K | – | 1378 |
|
|
2020
Q3 | $625K | Buy |
+42,177
| New | +$625K | 0.1% | 275 |
|
|
2020
Q2 | – | Sell |
-40,459
| Closed | -$475K | – | 832 |
|
|
2020
Q1 | $475K | Buy |
40,459
+12,900
| +47% | +$151K | 0.12% | 189 |
|
|
2019
Q4 | $648K | Buy |
+27,559
| New | +$648K | 0.08% | 469 |
|